Only Yervoy and Eliquis on the list will live up to potential, which is why BMY acquired AMLN, and pushed further into HCV. As good as BMY's pipeline relative to other big pharmas, they still need revenue to fill in the gap for the next a few years due to loss of patent.
Market Data 
Markets 
AI
